Aharon Schwartz

Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel.

CureTech Ltd. operates as a biotechnology company. It develops novel and immune modulating products for the treatment and control of cancer. The company was founded by Michael Schickler in 1995 and is headquartered in Yavne, Israel.

DenX Ltd. is engaged in manufacturing of dental equipment. The firm develops and markets image guided technology for dental training and clinical implementation. The company was founded by Hayka Alon in 1994 and is headquartered in Jerusalem, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel.

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.

Yissum Research Development Co. Ltd. (Yissum Research) is a venture capital subsidiary of The Hebrew University of Jerusalem founded in 1964. The firm is headquartered in Jerusalem, Israel.

BioMAS Ltd. is an Israeli pharmaceutical company that was founded in 2000. The private company is based in Jerusalem, Israel and develops drugs that are based on tellurium.

VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.

Integra Holdings Ltd. operates as a holding company. It invests in the pharmaceutical industry. The company was founded in 2012 and is headquartered in Jerusalem, Israel.

Barcode Diagnostics Ltd. is engaged in developing a product that assesses the efficacy of different cancer drugs directly on the tumor within the body to select the optimal personalized treatment for each patient. The company was founded by Ronen Eavri, Annie Sabbah, and Avi Schroeder in February 2017 and is headquartered in Nazareth, Israel.

Anthill Scale Ventures is a venture capital firm. The firm was founded in 2016 by Prasad Vanga. The firm headquartered in Hyderabad, India with additional office in Singapore, US and Israel.

D Pharm Ltd. provides drug development services.